Show simple item record

dc.contributor.authorGutiérrez Saborido, Daniel
dc.contributor.authorGutiérrez-Valencia, Alicia
dc.contributor.authorGonzález Domenech, Carmen María
dc.contributor.authorLópez Ruz, Miguel Ángel
dc.contributor.authorRaffo Márquez, Miguel
dc.contributor.authorOmar, Mohamed
dc.contributor.authorGirón González, José Antonio 
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2024-11-21T11:01:38Z
dc.date.available2024-11-21T11:01:38Z
dc.date.issued2019
dc.identifier.issn1432-0584
dc.identifier.issn0939-5555
dc.identifier.urihttp://hdl.handle.net/10498/33880
dc.description.abstractThe change in the incidence of lymphomas in function of the presence or absence of sustained virological response after anti-hepatitis C therapy in a cohort of human immunodeficiency (HIV)-hepatitis C (HCV) viruses coinfected patients was analyzed. A prospective cohort of 755 HIV-HCV coinfected patients who received their first anti-HCV therapy, based on interferon + ribavirin schemas, was evaluated. Incidence and histologic types of lymphomas were analyzed in two periods: (1) before administration of anti-HCV therapy and (2) after anti-HCV therapy. The association between lymphoma incidence and demographic, HIV- (minimum CD4+ cell count and CD4+ cell count at diagnosis of lymphoma, antiretroviral therapy, maximal HIV load and HIV load at diagnosis of lymphoma) and HCV-related variables (HCV load, genotype, sustained viral response to anti-HCV therapy) were analyzed. A total of 13 lymphomas [incidence rate (95% confidence interval), 0.72 (0.33-1.11) × 1000 person-years, time from HIV diagnosis to lymphoma diagnosis (median, interquartile range), 15 (11-19) years] were diagnosed. Nine of them were non-Hodgkin and four Hodgkin lymphomas. The median CD4+ T cell count at diagnosis of lymphoma was 457/mm3, with only two cases with values lower than 200/mm3. The incidence rate of non-Hodgkin lymphomas was similar pre- and post-anti HCV therapy [0.33 (0.00-0.65) vs 0.68 (0.08-1.26) × 1000 person-years, respectively, p > 0.05]. Patients with sustained virologic HCV response showed similar incidence rate of lymphomas than that of those without anti-HCV response. In conclusion, anti-HCV therapy does not modify the incidence rate of lymphomas in HIV-HCV coinfected patients.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSPRINGERes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceAnn Hematol. 2019 Aug;98(8):1953-1959.es_ES
dc.subjectHIVes_ES
dc.subjectHepatitis C viruses_ES
dc.subjectNon-Hodgkin lymphomaes_ES
dc.subjectHodgkin lymphomaes_ES
dc.subjectInterferon alphaes_ES
dc.subjectRibavirines_ES
dc.titleIncidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapyes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsclosed accesses_ES
dc.identifier.doi10.1007/s00277-019-03700-3
dc.type.hasVersionNAes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional